Viridian Therapeutics, Inc./DE Current Liabilities
Viridian Therapeutics, Inc./DE (VRDN) had Current Liabilities of $63.79 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Liabilities, Current $63.79M.
- 2026-03-31: Liabilities, Current $51.80M.
- 2025-12-31: Liabilities, Current $70.70M.
- 2025-09-30: Liabilities, Current $50.70M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $63.79M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $51.80M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $70.70M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $50.70M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $52.59M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $33.73M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $47.87M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $41.36M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $36.76M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $26.13M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $26.64M 10-K · filed 2025-03-03 | |
| 2023-09-30 | $23.25M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $28.66M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $29.59M 10-Q · filed 2023-05-10 | |
| 2022-12-31 | $33.35M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $25.21M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $21.39M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $14.39M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $13.64M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $14.34M 10-Q · filed 2021-11-05 | |
| 2021-06-30 | $16.83M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $16.44M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $10.67M 10-K · filed 2022-03-11 | |
| 2020-09-30 | $7.56M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $6.72M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $8.66M 10-Q · filed 2020-05-08 | |
| 2019-12-31 | $10.18M 10-K · filed 2021-03-26 | |
| 2019-09-30 | $10.38M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $9.15M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $6.86M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $6.73M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $6.83M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $4.28M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $4.14M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $3.90M 10-K · filed 2019-03-14 | |
| 2017-09-30 | $6.53M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $6.63M 10-Q · filed 2017-08-11 | |
| 2017-03-31 | $7.28M 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $6.88M 10-K · filed 2018-03-15 | $4.58M 10-K · filed 2017-03-24 |
| 2016-09-30 | $2.85M 10-Q · filed 2016-10-26 | |
| 2016-06-30 | $2.60M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $2.44M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $2.47M 10-K · filed 2017-03-24 | |
| 2015-09-30 | $2.11M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $2.08M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $2.50M 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $1.99M 10-K · filed 2016-03-21 | |
| 2014-09-30 | $2.00M 10-Q · filed 2014-11-14 | |
| 2014-06-30 | $2.14M 10-Q · filed 2014-08-14 | |
| 2013-12-31 | $27.30M 10-K · filed 2015-03-27 | $27.30M 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |